Martin Babler - Net Worth and Insider Trading

Martin Babler Net Worth

The estimated net worth of Martin Babler is at least $6 Million dollars as of 2024-04-27. Martin Babler is the President, CEO of Principia Biopharma Inc and owns about 58,344 shares of Principia Biopharma Inc (PRNB) stock worth over $6 Million. Details can be seen in Martin Babler's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Martin Babler has not made any transactions after 2020-06-23 and currently still holds the listed stock(s).

Transaction Summary of Martin Babler

To

Martin Babler Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Martin Babler owns 6 companies in total, including Principia Biopharma Inc (PRNB) , Neoleukin Therapeutics Inc (NLTX) , and ZS Pharma Inc (ZSPH) among others .

Click here to see the complete history of Martin Babler’s form 4 insider trades.

Insider Ownership Summary of Martin Babler

Ticker Comapny Transaction Date Type of Owner
PRNB Principia Biopharma Inc 2020-09-28 director & President & CEO
NLTX Neoleukin Therapeutics Inc 2020-09-08 director
ZSPH ZS Pharma Inc 2015-12-17 director
INFIQ Infinity Pharmaceuticals Inc 2008-05-22 director
PRLD Prelude Therapeutics Inc 2021-07-19 director
OMEG Omega Alpha SPAC 2021-01-06 director

Martin Babler Latest Holdings Summary

Martin Babler currently owns a total of 1 stock. Martin Babler owns 58,344 shares of Principia Biopharma Inc (PRNB) as of June 23, 2020, with a value of $6 Million.

Latest Holdings of Martin Babler

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PRNB Principia Biopharma Inc 2020-06-23 58,344 100.05 5,837,317

Holding Weightings of Martin Babler


Martin Babler Form 4 Trading Tracker

According to the SEC Form 4 filings, Martin Babler has made a total of 3 transactions in Principia Biopharma Inc (PRNB) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Principia Biopharma Inc is the sale of 15,000 shares on June 23, 2020, which brought Martin Babler around $927,900.

Insider Trading History of Martin Babler

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Martin Babler Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Martin Babler Ownership Network

Ownership Network List of Martin Babler

No Data

Ownership Network Relation of Martin Babler


Martin Babler Owned Company Details

What does Principia Biopharma Inc do?

Who are the key executives at Principia Biopharma Inc?

Martin Babler is the director & President & CEO of Principia Biopharma Inc. Other key executives at Principia Biopharma Inc include Chief Medical Officer Dolca Thomas , Chief Development Officer Stefani Wolff , and Chief Scientific Officer David M Goldstein .

Principia Biopharma Inc (PRNB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Principia Biopharma Inc (PRNB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Principia Biopharma Inc (PRNB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Principia Biopharma Inc (PRNB)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Principia Biopharma Inc Insider Transactions

No Available Data

Martin Babler Mailing Address

Above is the net worth, insider trading, and ownership report for Martin Babler. You might contact Martin Babler via mailing address: C/o Infinity Pharmaceuticals, Inc., 780 Memorial Drive, Cambridge Ma 02139.

Discussions on Martin Babler

No discussions yet.